Welcome to LookChem.com Sign In|Join Free

CAS

  • or

101910-86-5

Post Buying Request

101910-86-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

101910-86-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 101910-86-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,9,1 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 101910-86:
(8*1)+(7*0)+(6*1)+(5*9)+(4*1)+(3*0)+(2*8)+(1*6)=85
85 % 10 = 5
So 101910-86-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H13NO5S/c1-10-5-4-7-2-3-9(8(11)6-7)15-16(12,13)14/h2-3,6,10-11H,4-5H2,1H3,(H,12,13,14)

101910-86-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name [2-hydroxy-4-[2-(methylamino)ethyl]phenyl] hydrogen sulfate

1.2 Other means of identification

Product number -
Other names 1,2-Benzenediol,4-(2-(methylamino)ethyl)-,1-(hydrogen sulfate)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:101910-86-5 SDS

101910-86-5Downstream Products

101910-86-5Relevant articles and documents

Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines - Synthesis of ibopamine metabolites

Casagrande,Santangelo,Saini,Doggi,Gerli,Cerri

, p. 291 - 303 (2007/10/02)

The therapeutic usefulness of intravenously infused dopamine in congestive heart failure and in shock prompted us to synthesize a wide series of 3,4-O-diesters of dopamine and N-substituted derivatives to obtain an orally active dopamine-like prodrug having adequate absorption and duration of action. The pharmacological results and in particular, the hemodynamic studies in the dog led to the selection of ibopamine, i.e. the 3,4-diisobutyryl ester of N-methyldopamine and to its development as a useful drug for the chronic treatment of congestive heart failure. The choice of ibopamine from among several analogs was also influenced by other favourable properties such as good chemical stability in pharmaceutical formulations and in the biopharmaceutical phases of the absorption, and fast enzymatic activation of the prodrug by plasma and peripheral tissue esterases; the latter property appeared desirable to avoid any accumulation in the central nervous system and consequent undesired side effects. The isomeric mixture of 3-O- and 4-O- isobutyrates of N-methyldopamine as well as the main conjugated metabolites, i.e. the 3-O- and 4-O-sulphate and 4-O-β-glucuronide of N-methyldopamine were synthesized as analytical references in metabolic studies and for the investigation of their pharmacokinetic and pharmacological properties. Dopamine O-sulphates were also prepared using the methods developed for the corresponding N-methyl derivatives.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 101910-86-5